Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$82,323.00-1.41%ETH$2,533.48-1.48%GOLD$4,146.30+0.14%OIL$92.57+4.86%
Smart Investors Daily
SID Premium
NL

NASDAQ · NLSP

NLS Pharmaceutics AG

Healthcare · Biotechnology

$2.91

Down-$0.42 (-12.61%)

Updated Oct 8, 2026, 12:48 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.22M
P/E ratio
-0.72
Dividend yield
0.00%
52-week range
— – —
Volume
113.99K
Avg. volume
75.08K

Price performance · NLSP

NLSP price history

1M range · 0 trading sessions · Daily adjusted prices

NLSP does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest NLSP news

The latest Smart Investors Daily articles mentioning NLSP.

Stock researchCompany · Overview

NLSP research

Overview

Company profile and research snapshot.

Company profile

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NLSP recent ratings
DateFirmRatingTarget
Sep 14, 2023Maxim GroupHold—
Dec 8, 2022Maxim GroupBuy—
Nov 8, 2022Maxim GroupHold—
Sep 6, 2022Laidlaw & Co.Buy—
Mar 12, 2021Brookline CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Nov 3, 2025

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform, today announced that it has posted an investor presentation on its website.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By